Rachael Sirianni to Antineoplastic Agents
This is a "connection" page, showing publications Rachael Sirianni has written about Antineoplastic Agents.
Connection Strength
0.301
-
Chaudhuri S, Fowler MJ, Baker C, Stopka SA, Regan MS, Sablatura L, Broughton CW, Knight BE, Stabenfeldt SE, Agar NYR, Sirianni RW. ?-Cyclodextrin-poly (?-Amino Ester) Nanoparticles Are a Generalizable Strategy for High Loading and Sustained Release of HDAC Inhibitors. ACS Appl Mater Interfaces. 2021 May 12; 13(18):20960-20973.
Score: 0.124
-
Sandberg DI, Yu B, Patel R, Hagan J, Miesner E, Sabin J, Smith S, Fletcher S, Shah MN, Sirianni RW, Taylor MD. Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial. J Neurooncol. 2019 Jan; 141(2):449-457.
Score: 0.105
-
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ, Piepmeier JM, Saltzman WM. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):11751-6.
Score: 0.072